SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rallies on fears that escalating Middle East conflict and attacks on tankers and energy infrastructure could disrupt oil supplies, with traders also citing tight inventories. The community is split between bulls expecting further gains and bears who see a crowded, speculation-driven war premium that could unwind if diplomacy advances or supply concerns ease.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a sharp selloff across AI infrastructure and neocloud stocks, fueled by worries about financing costs, debt, and whether AI buildout spending will earn adequate returns. Traders are split on whether the oversold rebound signals stabilization or is a bull trap, with some arguing Nebius is better positioned than more debt-heavy peers.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Small caps are under pressure amid hotter inflation readings and concerns that interest rates may stay higher, with traders noting the Russell 2000s sensitivity to borrowing costs and its technical weakness. Some see oversold conditions and sector rotation as support for a rebound, while others expect further downside if key support fails.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs new index rules have raised the possibility that Strategy could be removed from major benchmarks, fueling concerns about forced passive-fund selling and adding pressure amid Bitcoin volatility. Traders are split between expecting further downside and buying the dip, with dilution and the companys preferred-stock buyback strategy also drawing criticism; removal has not been confirmed.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStops reminder that its shareholder warrants are nearing expiration is driving attention, with traders focused on whether the shares can rise above the exercise price before the deadline. Bears expect the warrants to expire worthless, avoiding dilution, while bulls speculate that Ryan Cohen may take action to lift the stock or extend the deadline.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention amid a volatile rebound after a sharp semiconductor selloff, as traders debate whether AI infrastructure spending can generate sufficient returns and whether debt risks at companies such as CoreWeave signal broader trouble. Bears see more downside if capex and financing concerns persist, while bulls view the pullback as overdone and expect upcoming earnings and guidance to reinforce AI-chip demand.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows is being linked to concerns about Trumps political standing ahead of the midterms and doubts about the companys business prospects, including Truth Social engagement. The discussion is overwhelmingly bearish, though some traders see a potential bounce or short squeeze.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is drawing attention amid a sharp, prolonged pullback and a wider semiconductor selloff, with traders debating whether concerns about AI spending, financing, and returns signal a broader downturn. Many blame CEO Hock Tans comments likening AI investing to gambling for worsening sentiment, while others view the selloff as a buying opportunity.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Colas new U.S. beverage partnership with KFC, replacing Pepsi at its restaurants, is drawing attention alongside KOs recent breakout and strength versus weaker tech stocks. Traders are broadly bullish on the momentum and defensive appeal, though some see the shares as stretched and expect resistance or a pullback.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

A sharp, volatile pullback has investors focused on whether CLS can hold support, with some traders buying the dip while others expect further declines. The selloff is being weighed against optimism about AI-infrastructure demand and an upcoming earnings report, though traders disagree on whether that optimism is already priced in.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VERAXA Biotech (NASDAQ: VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The in vivo study demonstrated significant tumor regression in a breast cancer model following a single 3 [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on its strategy to implement U.S. Food and Drug Administration “FDA”-aligned New Approach Methodologies “NAMs” across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines and significantly reduce animal testing. [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress

VERAXA Biotech (NASDAQ: VRXA) is shifting its focus to advancing its oncology pipeline and implementing industrial partnerships for its technology platforms and products following the completion of its business combination and commencement of Nasdaq trading in June 2026. Xlife Sciences AG (SIX: XLS) said VERAXA secured a financing base to support its next development steps [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is entering a new phase of development following its transition to the NASDAQ market and a series of scientific and corporate milestones that have expanded the company’s focus around its proprietary BiTAC(R) platform. The Swiss biotechnology company began trading on the NASDAQ Capital [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed Raju Willener as chief financial officer, adding a finance executive with more than three decades of international capital-markets experience as the biotechnology company works to advance its oncology pipeline. The appointment is effective immediately. Willener will report to Chief Executive Officer [&#8230;]

VERAXA Biotech (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy

VERAXA Biotech (NASDAQ: VRXA) is developing a new generation of antibody-based cancer therapies at a time when oncology research is increasingly focused on a difficult question: how can powerful treatments be made more selective without sacrificing their ability to kill cancer cells? The wiss biotechnology company is approaching that problem through a portfolio of antibody-drug [&#8230;]

VERAXA Biotech Designates Raju Willener as CFO

VERAXA Biotech Designates Raju Willener as CFO...

VERAXA Biotech (NASDAQ: VRXA) Appoints Raju Willener as Chief Financial Officer

VERAXA Biotech (NASDAQ: VRXA)&#160;a developer of next-generation antibody-based cancer therapies, announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener brings more than three decades of international financial leadership experience spanning global capital markets, investment banking, corporate finance, asset management and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, [&#8230;]

VERAXA Biotech (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, and Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, have reached an early research milestone in their collaboration to develop antibody oligonucleotide conjugates (“AOCs”), providing VERAXA with an initial proof point for applying its […]

VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has moved its VXA-222 bispecific antibody-drug conjugate program into the next stage of development after completing the initial phase of its collaboration with OmniAb, giving the biotechnology company a new development milestone while it continues expanding the intellectual-property estate underpinning its antibody technology [&#8230;]

Veraxa Biotech Holding AG engages in operating an oncology-focused biotechnology company, which is the Veraxa Biotech AG (Company). The Company focuses on the development of novel antibody-based drug platforms for the treatment of cancer. The company was founded on June 25, 2025 and is headquartered in Zurich, Switzerland.

Veraxa Biotech AG

Bearish Sentiment

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$1.00
Prev Close	$1.11
Open	$1.10
Dividend Yield	0.00%
50-Day Moving Average	$1.48
Beta	0.57
Avg. Volume	311,101.82
PE Ratio	4.67

52-Week High	$27.36
52-Week Low	$1.00
Market Capitalization	$163.98M
EPS (Annual)	$0.2842
Price to Book	-0.44
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

VRXA Fundamentals